Funded by Pfizer, and in partnership with Bristol University, AvonCAP is a large surveillance study on patients presenting to hospital with a lower respiratory tract infection (LRTI).
Accurate incidence rates of LRTI remain elusive, and the impact of COVID-19 on respiratory disease burden is unclear. Accurate incidence rates of vaccine-preventable infection are required to assess the potential population-level impact of vaccination recommendations. On this basis, the AvonCAP study seeks to measure the true burden of acute respiratory disease during and after the COVID-19 pandemic.
Patients who are admitted with LRTI will be approached and asked for consent to some extra samples being taken (bloods, urine and throat swab). This study will be recruiting over the next 3 years at NBT, hoping to recruit 6000-10000 patients per year.